Image by Getty Images via Daylife
Roche wants Genentech and it’s sick of waiting for a deal.
Six months after a special committee for the biotech firm’s board of directors rejected Roche’s offer of $43.7 billion or $89 a share, Roche has switched gears and dropped the offer to $86.50 per share and is taking negotiations to [...]
Roche Unsweetens Genentech Pot and Takes it to the Shareholders